Urinary Tract Infection Therapeutics Market Growth, Size, Trends, Revenue and Future Outlook

Urinary Tract Infection Therapeutics Market Size- By Drug, By Indication- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Urinary Tract Infection Therapeutics Market Size- By Drug, By Indication- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Published: Jan 2024 Report ID: HLCA2411 Pages: 1 - 235 Formats*:     
Category : Healthcare
Urinary Tract Infection Therapeutics Market Introduction and Overview 

According to SPER Market Research, the Global Urinary Tract Infection Therapeutics Market is estimated to reach USD 12.13 Billion by 2033 with a CAGR of 3.1%.

The report includes an in-depth analysis of the Global Urinary Tract Infection Therapeutics Market, including market size and trends, product mix, applications, and supplier analysis. Infections that affect any component of the urinary system, such as the kidneys, bladder, ureters, and urethra, are referred to as urinary tract infections. Bacteria that enter the urinary tract through the urethra are the main cause of these illnesses. Symptoms of urinary tract infections (UTIs) include burning or pain when urinating, murky or bloody urine, and urgency. In order to avoid consequences and recurrent infections, prompt diagnosis and adequate treatment are essential.

  • October 2021: The US Food and Drug Administration (FDA) received a new drug application (NDA) from Spero Therapeutics Inc. requesting clearance for tebipenem HBr tablets to treat complicated UTIs (cUTIs), including pyelonephritis, brought on by susceptible microorganisms.
  • September 2021: Biapenem was introduced by BDR Pharma, a top generic pharmaceutical company in India, to treat patients with urinary tract infections, lower respiratory infections, and intra-abdominal infections.
Urinary Tract Infection Therapeutics Market
Market Opportunities and Challenges

A greater emphasis on the creation of innovative medications is anticipated to offer substantial expansion opportunities for participants in the worldwide market for the treatment of urinary tract infections. It is anticipated that increased R&D will also offer profitable expansion opportunities for companies operating in the urinary tract infection treatment industry. Complicated UTIs are predicted to become more common during the projection period as a result of rising UTI recurrence rates, rising bacterial resistance in UTI patients, and overuse of antibiotics. The need for novel urinary tract infection treatments (drugs) is therefore anticipated to rise globally as a result, and this pattern is anticipated to persist throughout the projected period, propelling the market's expansion. Additionally, rising consumer awareness of the link between diabetes and obesity and bladder dysfunction, a greater emphasis on the creation of novel treatments, and the quick adoption of cutting-edge technologies for UTI treatment are some of the major trends propelling the market for urinary tract infection treatments as a whole.

The development of the worldwide urine tract infection treatment market is anticipated to be hampered by side effects related to the use of UTI medications. For example, the expansion of the urinary tract infection therapeutic market over the projected period may be hindered by side effects associated with UTI therapeutics like fluoroquinolones, such as fluctuations in blood sugar levels and central nervous system disorders like insomnia, seizures, and anxiety. The development of the worldwide market for treatments for urinary tract infections is also predicted to be hampered by a lack of awareness among people in developing and impoverished nations. 

Urinary Tract Infection Therapeutics Market


Market Competitive Landscape
The global market for treatments for urinary tract infections is very competitive, with a number of major companies present. To increase their market presence, these businesses concentrate on tactics including alliances, product launches, and mergers and acquisitions. The major key players in the Global Urinary Tract Infection Therapeutics Market are: Almirall SA, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Cipla Inc., Dr. Reddys Laboratories Ltd, GlaxoSmithKline PLC, Merck & Co. Inc, Novartis AG, Pfizer, Shionogi & Co. Ltd., Others.

Scope of the Report:
 Report Metric Details
 Market size available for years 2019-2033
 Base year considered 2022
 Forecast period 2023-2033
 Segments coveredBy Drug, By Indication
 Regions coveredAsia-Pacific, Europe, Middle East and Africa, North America, Latin America
 Companies CoveredAlmirall SA, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Cipla Inc., Dr. Reddys Laboratories Ltd, GlaxoSmithKline PLC, Merck & Co. Inc, Novartis AG, Pfizer, Shionogi & Co. Ltd., Others.
COVID-19 Impact on Global Urinary Tract Infection Therapeutics Market
The market for treatments for urinary tract infections has been significantly impacted by the COVID-19 pandemic, as has the whole global healthcare sector. The market dynamics have been impacted by shifts in patient behaviour, disruptions in supply chains, and the reallocation of healthcare resources towards pandemic management. On the other hand, the long-term management of UTIs is probably going to benefit from the increased emphasis on infection prevention and cleanliness practices.

Key Target Audience:
  • Pharmaceutical Companies
  • Healthcare Providers
  • Research and Development Teams
  • Patients and Caregivers
  • Health Insurance Providers
  • Government Health Departments
  • Pharmacy and Retail Chains
  • Others

Our in-depth analysis of the Urinary Tract Infection Therapeutics Market includes the following segments:
By Drug
  • Aminoglycoside Antibodies
  • Azoles and Amphotericin B
  • Cephalosporin
  • Nitrofurans
  • Penicillin and Combinations
  • By Indication
  • Complicated UTI
  • Neurogenic Bladder Infection
  • Recurring Complicated UTI
  • Uncomplicated UTI
  • Other Indications
  • By Region:
  • Asia-Pacific
  • Europe
  • Middle East & Africa
  • North America
  • Latin America
  • Key Topics Covered in the Report:
    • Global Urinary Tract Infection Therapeutics Market Size (FY’2023-FY’2033)
    • Overview of Global Urinary Tract Infection Therapeutics Market
    • Segmentation of Global Urinary Tract Infection Therapeutics Market By Drug (Aminoglycoside Antibodies, Azoles and Amphotericin B, Cephalosporin, Nitrofurans, Penicillin and Combinations, Quinolones, Sulphonamides, Tetracycline, Other Drugs)
    • Segmentation of Global Urinary Tract Infection Therapeutics Market By Indication (Complicated UTI, Neurogenic Bladder Infection, Recurring Complicated UTI, Uncomplicated UTI, Other Indications)
    • Statistical Snap of Global Urinary Tract Infection Therapeutics Market 
    • Expansion Analysis of Global Urinary Tract Infection Therapeutics Market 
    • Problems and Obstacles in Global Urinary Tract Infection Therapeutics Market
    • Competitive Landscape in the Global Urinary Tract Infection Therapeutics Market
    • Impact of COVID-19 and Demonetization on Global Urinary Tract Infection Therapeutics Market 
    • Details on Current Investment in Global Urinary Tract Infection Therapeutics Market
    • Competitive Analysis of Global Urinary Tract Infection Therapeutics Market 
    • Prominent Players in the Global Urinary Tract Infection Therapeutics Market 
    • SWOT Analysis of Global Urinary Tract Infection Therapeutics Market 
    • Global Urinary Tract Infection Therapeutics Market Future Outlook and Projections (FY’2023-FY’2033)
    • Recommendations from Analyst
    1. Introduction
    1.1. Scope of the report
    1.2. Market segment analysis

    2. Research Methodology
    2.1. Research data source
    2.1.1. Secondary Data
    2.1.2. Primary Data
    2.1.3. SPER’s internal database
    2.1.4. Premium insight from KOL’s
    2.2. Market size estimation
    2.2.1. Top-down and Bottom-up approach
    2.3. Data triangulation

    3. Executive Summary

    4. Market Dynamics
    4.1. Driver, Restraint, Opportunity and Challenges analysis
    4.1.1. Drivers
    4.1.2. Restraints
    4.1.3. Opportunities
    4.1.4. Challenges
    4.2. COVID-19 Impacts of the Global Urinary Tract Infection Therapeutics Market 

    5. Market variable and outlook
    5.1. SWOT Analysis
    5.1.1. Strengths
    5.1.2. Weaknesses
    5.1.3. Opportunities
    5.1.4. Threats
    5.2. PESTEL Analysis
    5.2.1. Political Landscape
    5.2.2. Economic Landscape
    5.2.3. Social Landscape
    5.2.4. Technological Landscape
    5.2.5. Environmental Landscape
    5.2.6. Legal Landscape
    5.3. PORTER’s Five Forces 
    5.3.1. Bargaining power of suppliers
    5.3.2. Bargaining power of buyers
    5.3.3. Threat of Substitute
    5.3.4. Threat of new entrant
    5.3.5. Competitive rivalry
    5.4. Heat Map Analysis

    6. Competitive Landscape
    6.1. Global Urinary Tract Infection Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type 
    6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Urinary Tract Infection Therapeutics Market 
     
    7. Global Urinary Tract Infection Therapeutics Market, By Drug (USD Million)
    7.1. Global Urinary Tract Infection Therapeutics Market Value Share and Forecast, By Drug, 2023-2033
    7.2. Aminoglycoside Antibodies
    7.3. Azoles and Amphotericin B
    7.4. Cephalosporin
    7.5. Nitrofurans
    7.6. Penicillin and Combinations
    7.7. Quinolones
    7.8. Sulphonamides
    7.9. Tetracycline
    7.10. Other Drugs 

    8. Global Urinary Tract Infection Therapeutics Market, By Indication (USD Million)
    8.1. Global Urinary Tract Infection Therapeutics Market Value Share and Forecast, By Indication, 2023-2033
    8.2. Complicated UTI
    8.3. Neurogenic Bladder Infection
    8.4. Recurring Complicated UTI
    8.5. Uncomplicated UTI
    8.6. Other Indications 

    9. Global Urinary Tract Infection Therapeutics Market Forecast, 2019-2033 (USD Million)
    9.1. Global Urinary Tract Infection Therapeutics Market Size and Market Share

    10. Global Urinary Tract Infection Therapeutics Market, By Drug, 2019-2033 (USD Million)
    10.1. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Drug (2019-2026)
    10.2. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Drug (2027-2033)

    11. Global Urinary Tract Infection Therapeutics Market, By Indication, 2019-2033 (USD Million)
    11.1. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Indication (2019-2026)
    11.2. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Indication (2027-2033)

    12. Global Urinary Tract Infection Therapeutics Market, By Region, 2019-2033 (USD Million)
    12.1. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Region (2019-2026)
    12.2. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Region (2027-2033)
    12.3. Asia-Pacific
    12.3.1. Australia
    12.3.2. China
    12.3.3. India
    12.3.4. Japan
    12.3.5. South Korea
    12.3.6. Rest of Asia-Pacific
    12.4. Europe
    12.4.1. France
    12.4.2. Germany
    12.4.3. Italy
    12.4.4. Spain
    12.4.5. United Kingdom
    12.4.6. Rest of Europe
    12.5. Middle East and Africa
    12.5.1. Kingdom of Saudi Arabia 
    12.5.2. United Arab Emirates
    12.5.3. Rest of Middle East & Africa
    12.6. North America
    12.6.1. Canada
    12.6.2. Mexico
    12.6.3. United States
    12.7. Latin America
    12.7.1. Argentina
    12.7.2. Brazil
    12.7.3. Rest of Latin America 

    13. Company Profile
    13.1. Almirall SA
    13.1.1. Company details
    13.1.2. Financial outlook
    13.1.3. Product summary 
    13.1.4. Recent developments
    13.2. AstraZeneca
    13.2.1. Company details
    13.2.2. Financial outlook
    13.2.3. Product summary 
    13.2.4. Recent developments
    13.3. Bayer AG
    13.3.1. Company details
    13.3.2. Financial outlook
    13.3.3. Product summary 
    13.3.4. Recent developments
    13.4. Bristol-Myers Squibb Company
    13.4.1. Company details
    13.4.2. Financial outlook
    13.4.3. Product summary 
    13.4.4. Recent developments
    13.5. Cipla Inc.
    13.5.1. Company details
    13.5.2. Financial outlook
    13.5.3. Product summary 
    13.5.4. Recent developments
    13.6. Dr. Reddys Laboratories Ltd
    13.6.1. Company details
    13.6.2. Financial outlook
    13.6.3. Product summary 
    13.6.4. Recent developments
    13.7. GlaxoSmithKline PLC
    13.7.1. Company details
    13.7.2. Financial outlook
    13.7.3. Product summary 
    13.7.4. Recent developments
    13.8. Merck & Co. Inc
    13.8.1. Company details
    13.8.2. Financial outlook
    13.8.3. Product summary 
    13.8.4. Recent developments
    13.9. Novartis AG
    13.9.1. Company details
    13.9.2. Financial outlook
    13.9.3. Product summary 
    13.9.4. Recent developments
    13.10. Pfizer
    13.10.1. Company details
    13.10.2. Financial outlook
    13.10.3. Product summary 
    13.10.4. Recent developments
    13.11. Shionogi & Co. Ltd.
    13.11.1. Company details
    13.11.2. Financial outlook
    13.11.3. Product summary 
    13.11.4. Recent developments
    13.12. Others 
     
    14. List of Abbreviations

    15. Reference Links

    16. Conclusion

    17. Research Scope

    SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

    The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

    SPER-Methodology-1

    SPER-Methodology-2

    SPER-Methodology-3


    Frequently Asked Questions About This Report
    Urinary Tract Infection Therapeutics Market is projected to reach USD 12.13 billion by 2033, growing at a CAGR of 3.1% during the forecast period.
    Urinary Tract Infection Therapeutics Market size from 2022. The Market is expected to reach USD 12.13 billion by 2033, at a CAGR of 3.1% during the forecast period.
    Urinary Tract Infection Therapeutics Market CAGR of 3.1% during the forecast period.
    Urinary Tract Infection Therapeutics Market size is 12.13 billion from 2023 to 2033.
    Urinary Tract Infection Therapeutics Market Segment is covered By Drug, By Indication.
    The North America is anticipated to have the highest market share in the Urinary Tract Infection Therapeutics Market.
    "The key players in the market include Companies Covered Almirall SA, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Cipla Inc., Dr. Reddys Laboratories Ltd, GlaxoSmithKline PLC, Merck & Co. Inc, Novartis AG, Pfizer, Shionogi & Co. Ltd., Others."
    Complicated UTIs are predicted to become more common during the projection period as a result of rising UTI recurrence rates, rising bacterial resistance in UTI patients, and overuse of antibiotics.
    Not able to find what you are looking for? Need customization in the existing report?
    Click Here
    PLACE AN ORDER
    • 15% off
       
      $ 4250
    • 20% off
               
      $ 5650
    • 25% off
           
      $ 7450
    Pre-Purchase Inquiry
    SEND AN INQUIRY
    NEED CUSTOMIZATION?
    Request Customization
    CALL OR EMAIL US
    US:
    India:
    Email:
    100% Secure Payment

    SPER American Express
    SPER VISA
    SPER Master Card
    SPER Mestro
    SPER Paypal
    SPER CCAvenues

    Join Our SPER Panel

    Our Global Clients

    Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
    SPER-Astellas Pharma
    SPER-Citi Bank
    SPER-Microsoft
    SPER-EY
    SPER-Sanofi
    SPER-p&g
    SPER-Johnson & Johnson
    SPER-SIEMENS
    SPER-LOREAL
    SPER-Pfizer
    SPER-IPSOS
    SPER-Heineken
    SPER-IQVIA
    SPER-Kankar IMRB
    SPER-PWC
    SPER-Astellas Pharma
    SPER-Citi Bank
    SPER-Microsoft
    SPER-EY
    SPER-Sanofi
    SPER-p&g
    SPER-Johnson & Johnson
    SPER-SIEMENS
    SPER-LOREAL
    SPER-Pfizer
    SPER-IPSOS
    SPER-Heineken
    SPER-IQVIA
    SPER-Kankar IMRB
    SPER-PWC

    SPER

    Market Research

    We are the leading, full-service global market research and consulting company.

    Certificates
    iso-1 iso-1 iso-1 ESOMAR
    Secure Payments
    SPER Payment Options
    Contact HR

     [email protected]

     +91-742-898-5650